TB Clinical Intensive Course
A TB Clinical Intensive Course will be held in Casper March 2 & 3. This course is designed for physicians, nurse, pharmacists, and other health care professionals who are involved in the management of patients with active and latent tuberculosis, supervise those who provide care for TB patients, or are infection control staff responsible for TB program management. The training will be held at the Wyoming Oil & Gas Conservation Commission Building. Please see this flyer or contact Brittany Wardle or Samantha Birch (contact info above).
Forms and Documents (English)
Tuberculosis (TB) Forms and Documents
Forms and Documents (Spanish)
Manual and Protocols
PUBLICATION COVER: Program information and publication date.
CHAPTER 1: INTRODUCTION TO MANUAL AND TB CONTROL Including Wyoming laws ans rules regarding TB control, objectives and standards, roles and responsibilities (program staff, consultants, public health agencies, private providers and laboratories).
CHAPTER 2: TB SURVEILLANCE Introduction to surveillance (purpose, policies, laws and rules), TB classification system, how to report TB, data collection forms, registry and document retention, genotyping, dissemination, evaluation.
CHAPTER 3: TARGETED TESTING FOR LATENT TB INFECTION Introduction including the purpose and policies surrounding targeted testing for latent TB, when to do targeted testing, how to increase targeted testing and treatment, screening in facilities.
CHAPTER 4: TB NOTIFICATIONS Introduction to notifications including purpose, pre-arrival medical screenings and policies, evaluation and follow-up of B1/B2 TB arrivals (including division of global migration and quarantine forms, patient follow-up, evaluation activities and treatment).
CHAPTER 5: DIAGNOSIS OF TB DISEASE Purpose, policy and forms for the diagnosis of TB disease, identification and follow-up of suspected TB cases, diagnosis of TB disease including medical history review, HIV screening, physical examinations, TB skin test and IGRA testing, radiography and bacteriologic examinations.
CHAPTER 6: TREATMENT OF TB DISEASE Purpose, policy and forms for the treatment of TB disease, basic treatment principles, regimens, dosages and durations of treatment, side effects and adverse reactions (monitoring, reporting), response to treatment, completion of therapy, post-treatment evaluation, treatments in special situations (including drug-resistant TB, HIV infection, alcohol use, liver disease, renal insufficiency and end-stage renal disease, TB associated with tumor necrosis factor-alpha antagonists, culture-negative pulmonary TB, extrapulmonary TB, pregnancy and breastfeeding, TB in children).
CHAPTER 7: DIAGNOSIS OF LATENT TB INFECTION Purpose, policy and forms for diagnosis of latent TB infection, high-risk groups, diagnosis through interferon-gamma release assays (IGRA) and Mantoux TB skin testing, candidates for mantoux TB skin testing, administration/ measurement/ interpretation of the TB skin test, HIV screening, follow-up activities and chest radiography.
CHAPTER 8: TREATMENT OF LATENT TB INFECTION Introduction, whom to treat (susceptible/ vulnerable contacts, TB skin test results of 5mm/ 10mm/ 15mm or more, treatment regimens and dosages, side effects and adverse reactions (monitoring and reporting). Adherence to treatment (monthly assessment and directly observed therapy), completion of therapy and special situations (including HIV/ Latent TB infection, alcohol use, pregnancy, breastfeeding.
CHAPTER 9: CASE MANAGEMENT Introduction (including purpose, policy, forms, acknowledgments), initial assessment (cultural sensitivity, language issues, patient’s medical records, assessment site, discharge planning, initial assessment activities), treatment plan components, activities and implementation. Ongoing assessment activities, monitoring for side effects/ adverse reactions/ bacterial/ and clinical improvements. Verifying completion of therapy, adequate course of treatment, calculating completion of therapy and closures other than completion. Evaluation activities, directly observed therapy (candidates, how to deliver, adherence to), incentives and enablers (eligible patients, available incentives), progressive interventions, types of legal orders and how to process them.
CHAPTER 10: CONTACT INVESTIGATION Introduction, basic steps and planning for contact investigation, factors predicting transmission and the decision to initiate contact investigation, index patient and transmission site information, contact evaluation and treatment, ongoing management activities and time frame of contact investigation activities. Infection period, index patient pre-interview preparation and general guidelines. Field investigation, contact priorities, evaluation, treatment and follow-up. When to expand contact investigation and low-priority contacts. Data management and evaluation of contact investigations, outbreak investigations and Wyoming TB outbreak response plan.
CHAPTER 11: LABORATORY SERVICES Introduction, available lab tests, specimen collection and shipment.
CHAPTER 12: PATIENT EDUCATION Introduction, general guidelines, language and comprehension barriers, education topics (diagnosis, contact investigation, isolation, side effects, adverse reactions, adherence), patient education materials.
CHAPTER 13: CONFIDENTIALITY Introduction, CDC guidance on HIPAA, Wyoming HIPAA policies, national confidentiality guidelines.
CHAPTER 14: TRANSFER NOTIFICATIONS Introduction, when and how to initiate/ issue a notification (both within and outside of the United States),
CHAPTER 15: SUPPLIES, MATERIALS, AND SERVICES Introduction, Mantoux TB skin testing supplies, Interferon Gamma Release Assay supplies, chest radiographs, specimen collection and shipment supplies, anti-tuberculosis medications, incentives and enablers, medical interpretation services, healthcare staff training and education.
CHAPTER 16: INFECTION CONTROL Introduction, Infection Control Measures (Administrative, Environmental, Personal respiratory protection), two-step TB skin testing, estimating infectiousness and determining non-infectiousness, airborne infection isolation,hospital discharge determinations, residential setting infection control measures, social settings (school, work, other), TB infection control inpatient care facilities and transportation vehicles (self-transport, healthcare workers, emergency medical services).
CHAPTER 17: GLOSSARY
Healthcare Employee TB Testing
All healthcare facilities should have policies and procedures in place to address TB screening for their employees based on current Wyoming Department of Health and CDC guidelines.
New guidelines to be distributed in 2016 (CLICK HERE) advise that each facility perform an individualized facility risk assessment and screen healthcare workers based on the risk of encountering TB in their work environment.
The WDH TB Facility Risk Assessment can be used to classify facilities into low, medium, or potential on-going risk. Low risk facilities have the option to eliminate yearly TST screening for their healthcare workers.
Wyoming and national TB rates are needed to complete a facility risk assessment. Those can be found on the Statistics button on this page. Even more in-depth guidance can be found in the CDC’s “Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005.” Click HERE
If you have further questions about facility risk assessments, please contact Samantha Birch at email@example.com or at 307-777-6563.